Cargando…

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

BACKGROUND: Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increasing the progression-free survival (PFS) time by pirfenidone. Recently, marginal decline in forced VC (FVC) has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taniguchi, Hiroyuki, Kondoh, Yasuhiro, Ebina, Masahito, Azuma, Arata, Ogura, Takashi, Taguchi, Yoshio, Suga, Moritaka, Takahashi, Hiroki, Nakata, Koichiro, Sato, Atsuhiko, Sugiyama, Yukihiko, Kudoh, Shoji, Nukiwa, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160381/ https://www.ncbi.nlm.nih.gov/pubmed/21756364 http://dx.doi.org/10.1186/1465-9921-12-93

Ejemplares similares

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
por: Azuma, Arata, et al.
Publicado: (2011)

Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
por: Ikeda, Kimiyuki, et al.
Publicado: (2020)

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability
por: Kamio, Koichiro, et al.
Publicado: (2014)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

A Case of Cutaneous Infection Caused by Mycobacterium Szulgai with Progression to Acute Respiratory Distress Syndrome
por: Ohta, Hiromitsu, et al.
Publicado: (2011)

Primary ciliary dyskinesia caused by a large homozygous deletion including exons 1–4 of DRC1 in Japanese patients with recurrent sinopulmonary infection
por: Keicho, Naoto, et al.
Publicado: (2019)

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2014)

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
por: Minegishi, Yuji, et al.
Publicado: (2020)

Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function
por: Nakamura, Atsushi, et al.
Publicado: (2013)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography
por: Hisata, Shu, et al.
Publicado: (2011)

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Gradual Increase of High Mobility Group Protein B1 in the Lungs after the Onset of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Ebina, Masahito, et al.
Publicado: (2011)

Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice
por: Nakamura, Akira, et al.
Publicado: (2003)

Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
por: Biondini, Davide, et al.
Publicado: (2018)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Epimorphin expression in interstitial pneumonia
por: Terasaki, Yasuhiro, et al.
Publicado: (2005)

The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study
por: Takaki, Makoto, et al.
Publicado: (2017)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
por: Sakayori, Masashi, et al.
Publicado: (2019)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Interstitial lung disease associated with drug therapy
por: Camus, P, et al.
Publicado: (2004)

Gene Mutations in Lung Cancer: Promising Predictive Factors for the Success of Molecular Therapy
por: Inoue, Akira, et al.
Publicado: (2005)

A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034)
por: Sakairi, Yuichi, et al.
Publicado: (2023)

The multifaceted role of pirfenidone and its novel targets
por: Macías-Barragán, José, et al.
Publicado: (2010)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Pirfenidone prevents acute kidney injury in the rat
por: Lima-Posada, Ixchel, et al.
Publicado: (2019)

Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
por: Polydorou, Christiana, et al.
Publicado: (2017)

Pirfenidone ameliorates the formation of choroidal neovascularization in mice
por: Bao, Yueqi, et al.
Publicado: (2020)

Pirfenidone regulates LPS mediated activation of neutrophils
por: Evani, Shankar J., et al.
Publicado: (2020)

Severe Photosensitivity Reaction After Pirfenidone Use
por: Choudhury, Saiara, et al.
Publicado: (2021)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vmd9d1ah346k0a12mtnvrv6rov